• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

9.82 EUR+0.20 %10.7. klo 18.29
5,653 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.20 %
+7.91 %
+8.75 %
-27.53 %
-30.85 %
-32.97 %
+175.07 %
+145.50 %
-98.38 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
79.3M EUR
Turnover
98.45K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
14.05.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications Press Release, Helsinki, 10 July 2026 at 9 AM (EEST) Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications Nexstim Plc (“Nexstim” or the “Company”) ...
7/10/2026, 6:05 AM
by Kyhnykeisari
35
Sinaptica is firing up its first machine this July in Florida, so the research continues, and we’re hoping for some strong results.
7/9/2026, 8:10 PM
18
Perhaps Köpi hasn’t listened to that podcast linked by @Kyhnykeisari yet; everyone should watch the section from 30:00-32:00 in particular. A direct link with a timestamp to that part, with a small pre-disclaimer: https://www.youtube.com/watch?v=2EFNW2SFkYw&t=1766s Pay attention ...
7/10/2026, 8:36 AM
17
Same here, this is growing nicely though, and there’s no pressure on the cash position either. The rest is just a matter of waiting. But as long as the setup seems to be playing out this well, there’s no reason to sell. And at this point, we should start seeing orders from new regions...
yesterday
by Informaatio
15
I’m in this case until the very end, so to speak. There are no dark clouds on the horizon. I don’t think it matters why some investment mogul is reducing their position, because there can be many personal reasons for that. Back in the day, they sold their Revenio stake at €28–29,...
7/10/2026, 11:35 AM
by Jorelyytikko
15
Sinaptica CEO as a guest
7/9/2026, 2:30 PM
by Kyhnykeisari
15
Positive news won’t drive the stock price up until there’s concrete information on the growth percentage at which this story is advancing. Nothing to do but wait for the H1 report on August 14th, unless bigger news comes out before then. Still, the story is progressing consistently...
7/10/2026, 7:17 AM
by Optimistinen verkkapöksy
11
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 15.05.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8.
2026

Interim report Q2'26

Press release10.07.2026 klo 09.00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release08.07.2026 klo 09.00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim
Press release07.07.2026 klo 09.00

Nexstim Receives Malaysian Authorization for Commercial Distribution of NBS System 6

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
New NBS 6 system order for Nexstim from USA
Analyst Comment06.07.2026 klo 09.17 by
Atte Riikola

New NBS 6 system order for Nexstim from USA

This is a new customer for the company

Nexstim
Press release03.07.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States

Nexstim
Significant one-time order for Nexstim
Analyst Comment12.06.2026 klo 09.28 by
Antti Siltanen

Significant one-time order for Nexstim

The one-time order for ten systems strengthens our confidence in this year's growth estimates.

Nexstim
Press release11.06.2026 klo 09.00

Nexstim Receives Order for Ten NBS 6 Systems from Distributor

Nexstim
Nexstim received a new sales authorization for the NBS 6 system in Australia
Analyst Comment04.06.2026 klo 08.48 by
Antti Siltanen

Nexstim received a new sales authorization for the NBS 6 system in Australia

The sales authorization expands the use of the NBS 6 system to diagnostics and rehabilitation.

Nexstim
Press release03.06.2026 klo 10.00

Nexstim granted authorization for commercial distribution of NBS System 6 for use in diagnostics and post-operative rehabilitation in Australia

Nexstim
Regulatory press release25.05.2026 klo 09.00

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Nexstim
Regulatory press release18.05.2026 klo 17.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release15.05.2026 klo 14.40

Nexstim Plc: Managers’ Transactions, Järnefelt

Nexstim
Regulatory press release15.05.2026 klo 14.40

Nexstim Plc: Managers’ Transactions, Hannula

Nexstim
Regulatory press release15.05.2026 klo 14.40

Nexstim Plc: Managers’ Transactions, Niemistö

Nexstim
Regulatory press release15.05.2026 klo 14.40

Nexstim Plc: Managers’ Transactions, Laine

Nexstim
Nexstim strengthens its balance sheet
Research15.05.2026 klo 09.00 by
Antti Siltanen

Nexstim strengthens its balance sheet

The 5 MEUR financing supports the growth strategy.

Nexstim
Regulatory press release13.05.2026 klo 17.00

Nexstim Plc: Managers’ Transactions, Hildén

Nexstim
Regulatory press release13.05.2026 klo 17.00

Nexstim Plc: Managers’ Transactions, Karvinen

Nexstim
Regulatory press release13.05.2026 klo 17.00

Nexstim Plc: Managers’ Transactions, Forss

Nexstim
Regulatory press release13.05.2026 klo 17.00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim